Mar 15, 2022 / 07:50PM GMT
Justin Hayward Burns - Barclays Bank PLC, Research Division - Research Analyst
All right. Good afternoon, everyone. Thanks for joining us at the 2022 Barclays Global Healthcare Conference. My name is Justin Burns. I'm an associate on the U.S. Biopharmaceuticals team, and it's my pleasure to introduce Dr. Vimal Mehta and BioXcel Therapeutics.
Vimal D. Mehta - BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director
Thank you, Justin. Thank you to our hosts at Barclays for the opportunity to present today, and good afternoon to all of you.
I will be making some forward-looking statements, and my goal today will be to introduce the company as well as provide you update that -- exciting things that are happening around our business for 2022.
So as you know, BioXcel Therapeutics is developing transformative medicines using AI-based approach, artificial intelligence-based approaches in neuroscience and immuno-oncology. Our lead products are -- 2 lead products are BXCL501 and BXCL701. 501 is investigational proprietary orally dissolving
BioXcel Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot